ArticleJournal of thrombosis and thrombolysis2026
Peli1 promotes sepsis-induced inflammation and coagulopathy by maintaining lipg stability in macrophages.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sepsis is marked by dysregulated inflammation and coagulopathy, with macrophages playing a central role. However, the molecular mechanisms linking macrophage dysfunction to sepsis-associated coagulopathy remain unclear. This study investigated the role of the E3 ubiquitin ligase Peli1 in sepsis progression and its downstream mechanism. Public scRNA-seq data from sepsis patients were analyzed to identify Peli1-associated immune signatures. Peli1 expression was validated in monocytes from sepsis patients and in CLP-induced septic mice. Peli1-deficient iBMDMs and myeloid cell-specific Peli1-deficient mice were used to assess its functional role. Transcriptomic profiling (RNA-seq), RT-qPCR, Western blotting, cycloheximide (CHX) chase assays, and co-immunoprecipitation (Co-IP) assays were performed to investigate the downstream molecular mechanisms and post-translational modifications. Peli1 was highly enriched in monocytes from fatal sepsis cases and markedly upregulated in monocytes from septic patients and CLP-induced septic mice. Peli1 deficiency attenuated macrophage inflammatory activation, improved platelet aggregation abnormalities, and enhanced survival in septic mice. Mechanistically, Lipg was identified as a crucial downstream target of Peli1 from transcriptomic analysis. Western blot and RT-qPCR validation confirmed that Peli1 predominantly regulated Lipg protein abundance through a post-transcriptional or post-translational mechanism, particularly under LPS-stimulated conditions. Peli1 was detected in the Lipg-immunoprecipitated complex, suggesting an association between Peli1 and Lipg. Further biochemical mapping revealed that Peli1 facilitated polyubiquitination specifically at the critical KR2 residue of Lipg to maintain its stability and shield it from proteasomal degradation. Ectopic restoration of Lipg successfully reversed the anti-inflammatory phenotypes and blunted cytokine production caused by Peli1 deficiency. Peli1 promoted sepsis-induced hyper-inflammation and coagulopathy by post-translationally maintaining Lipg stability in macrophages via site-specific ubiquitination. Target disruption of the Peli1-Lipg axis represents a promising therapeutic avenue to attenuate detrimental inflammation and immunothrombotic responses during sepsis.
Indexed as
Identifiers
42829412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.